Zeronac-T & Zeronac-ET is a specialized medication combining Ethamsylate BP and Tranexamic Acid to effectively control bleeding in pets. This combination therapy is designed to address both spontaneous and post-operative hemorrhage, abdominal hematomas, and accidental excess bleeding cases. Ethamsylate BP (250mg) helps stabilize capillary walls and reduces blood loss, while Tranexamic Acid (500mg) prevents the breakdown of fibrin, promoting clot formation and minimizing bleeding. Zeronac-T & Zeronac-ET offers an effective solution for managing bleeding in animals, ensuring rapid intervention in critical situations. The dosage is carefully tailored based on the animal's weight and condition, with recommendations ranging from 6.2mg to 12mg per kg for Ethamsylate and 10mg to 20mg per kg for Tranexamic Acid.
Spontaneous & post operative Hemorrhage
Abdominal hematoma
To control accidental excess bleeding cases
The two variations of Zeronac-T & Zeronac-ET—one as a 100mg injection (5x2ml) and the other as 10x10 tablets—offer flexibility in treatment based on the severity of the condition and the clinical setting. The injectable form is ideal for emergency situations requiring rapid action to control bleeding, providing fast absorption and onset of action for critically ill animals. On the other hand, the tablet form is more suitable for long-term management or home care, offering ease of administration and avoiding the need for injections. Together, these variations allow for tailored treatment to meet both acute and ongoing needs, ensuring the best outcome for the animal.
Zeronac ET/T combines Ethamsylate and Tranexamic Acid, both of which are highly effective in controlling hemorrhage. Ethamsylate promotes platelet aggregation and stabilizes capillary walls, reducing microvascular bleeding, while Tranexamic Acid inhibits the breakdown of fibrin clots, further preventing excessive blood loss. Together, they provide a dual mechanism to manage bleeding, both spontaneous and post-surgical.
Ethamsylate and Tranexamic Acid work synergistically to control different types of bleeding, from spontaneous hemorrhages to post-operative bleeding, abdominal hematomas, and accidental excess blood loss. This combination addresses both the immediate need for clot stabilization and the longer-term prevention of bleeding, making it ideal for a wide range of clinical conditions.
With both injectable and oral tablet forms available, Zeronac ET/T offers versatility in administration based on the clinical situation. The injectable form ensures rapid action in emergencies or critical care settings, while the oral tablets allow for continued therapy in stable conditions, providing long-term treatment and ease of administration at home. This flexibility ensures optimal patient care across various clinical scenarios.
Q
What are the key ingredients in Zeronac ET/T?
A
Zeronac ET/T contains Ethamsylate (250 mg) and Tranexamic Acid (500 mg) in each film-coated tablet. It also comes in an injectable form containing Tranexamic Acid (100 mg/ml). These active ingredients work together to effectively control bleeding and manage hemorrhage.
Q
How does Zeronac ET/T work to stop bleeding?
A
Zeronac ET/T works through a dual mechanism. Ethamsylate promotes platelet aggregation and stabilizes blood vessels to prevent microvascular bleeding, while Tranexamic Acid inhibits the breakdown of fibrin clots, thereby preventing excessive bleeding. Together, they provide comprehensive support in controlling bleeding in various medical conditions.
Q
What conditions can Zeronac ET/T be used for?
A
Zeronac ET/T is indicated for managing conditions involving spontaneous and post-operative hemorrhage, abdominal hematomas, and excessive bleeding due to accidents. It is especially useful for controlling bleeding in both acute and chronic cases, as well as during pre-operative care.
